Downloads: 57

Files in This Item:
File Description SizeFormat 
journal.pone.0216954.pdf1.47 MBAdobe PDFView/Open
Title: Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab
Authors: Yamauchi, Ichiro  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-4236-502X (unconfirmed)
Yasoda, Akihiro
Matsumoto, Shigemi  kyouindb  KAKEN_id
Sakamori, Yuichi
Kim, Young Hak
Nomura, Motoo
Otsuka, Atsushi
Yamasaki, Toshinari  kyouindb  KAKEN_id
Saito, Ryoichi
Kitamura, Morimasa  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-4875-4165 (unconfirmed)
Kitawaki, Toshio
Hishizawa, Masakatsu
Kawaguchi-Sakita, Nobuko
Fujii, Toshihito
Taura, Daisuke  kyouindb  KAKEN_id
Sone, Masakatsu  kyouindb  KAKEN_id
Inagaki, Nobuya
Author's alias: 山内, 一郎
八十田, 明宏
松本, 繁巳
阪森, 優一
金, 永学
野村, 基雄
大塚, 篤司
山﨑, 俊成
齊藤, 亮一
北村, 守正
北脇, 年雄
菱澤, 方勝
川口, 展子
藤井, 寿人
田浦, 大輔
曽根, 正勝
稲垣, 暢也
Issue Date: 14-May-2019
Publisher: Public Library of Science (PLoS)
Journal title: PLOS ONE
Volume: 14
Issue: 5
Thesis number: e0216954
Abstract: Background: Blocking the PD-1 pathway induces immune-related adverse events (irAEs) which often involve the thyroid gland (thyroid irAEs). Clinical features of a thyroid irAE including its predictability and relationship to prognosis remain to be elucidated. Methods: Two hundred consecutive patients treated with nivolumab at Kyoto University Hospital between September 1, 2014 and August 31, 2017 were included in a retrospective cohort study. We systematically determined and classified subclinical and overt thyroid irAEs based on data collected of serum free T4 and TSH levels. Baseline characteristics and detailed clinical data were analyzed, and analyses of overall survival (OS) excluded patients censored within 1 month from the first administration of nivolumab. Results: Sixty-seven patients (33.5%) developed thyroid irAEs and these were divided into a subclinical thyroid irAE group (n = 40, 20.0%) and an overt thyroid irAE group (n = 27, 13.5%). Patients with thyroid uptake of FDG-PET before treatment showed high incidences of overt thyroid irAE (adjusted odds ratio 14.48; 95% confidence interval [CI] 3.12–67.19), while the same relationship was not seen with subclinical thyroid irAE. Regarding the total cohort, the thyroid irAE (+) group had a significantly longer median OS than the thyroid irAE (−) group (16.1 versus 13.6 months, hazard ratio [HR] 0.61; 95% CI 0.39–0.93). In 112 non-excluded patients with lung cancer, the thyroid irAE (+) group similarly had a longer median OS than the thyroid irAE (−) group (not reached versus 14.2 months, HR 0.51; 95% CI 0.27–0.92). However, this observation was not seen in 41 non-excluded patients with malignant melanoma (12.0 versus 18.3 months, HR 1.54; 95% CI 0.67–3.43). Conclusions: By thyroid uptake of FDG-PET, overt thyroid irAEs could be predicted before nivolumab therapy. Thyroid irAEs related to good prognosis in lung cancer but might be inconclusive in malignant melanoma.
Rights: © 2019 Yamauchi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
URI: http://hdl.handle.net/2433/241628
DOI(Published Version): 10.1371/journal.pone.0216954
PubMed ID: 31086392
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.